Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

ACTIVE NOT RECRUITING

NCT05306457

PHASE1

CNS10-NPC-GDNF Delivered to the Motor Cortex for ALS

Sponsor: Cedars-Sinai Medical Center

View on ClinicalTrials.gov

Summary

The investigator is examining the safety of transplanting cells, that have been engineered to produce a growth factor, into the motor cortex (brain) of patients with Amyotrophic Lateral Sclerosis (ALS). The cells are called neural progenitor cells, which are a type of stem cell that can become several different types of cells in the nervous system. These cells have been derived to specifically become astrocytes, which is a type of neural cell. The growth factor is called glial cell line-derived neurotrophic factor, or GDNF. GDNF is a protein that promotes the survival of many types of neural cells. Therefore, the cells are called "CNS10-NPC-GDNF." The investigational treatment has been tested in people by delivering it to the spinal cord. However, it has only been delivered to the motor cortex of animals. In this study, we want to learn if CNS10-NPC-GDNF cells are safe to transplant into the motor cortex (brain) of people.

Official title: Human Neural Progenitor Cells Secreting Glial Cell Line-Derived Neurotrophic Factor (CNS10-NPC-GDNF) Delivered to the Motor Cortex for the Treatment of Amyotrophic Lateral Sclerosis

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

Start Date

2022-05-08

Completion Date

2026-10

Last Updated

2025-08-19

Healthy Volunteers

Conditions

Amyotrophic Lateral Sclerosis

Interventions

BIOLOGICAL

CNS10-NPC-GDNF

Unilateral injections of CNS10-NPC-GDNF into the motor cortex

Inclusion: 1. Confirmed diagnosis of ALS (Possible, Lab-supported Probable, Probable or Definite El Escorial Criteria) 2. Duration of ALS symptoms ≤ 36 months 3. Progressive weakness in upper extremities, with EMG supported evidence of denervation in both upper extremities 4. Forced Vital Capacity ≥50% of predicted normal in supine 5. Age: 18 years or older 6. Able to provide Informed Consent 7. Be geographically accessible to the study site and able to travel to study site for required visits 8. Have caregiver to assist in the transportation and care required by participation in the study 9. Not taking riluzole and/or edaravone or on a stable dose for ≥ 30 day 10. For women of child bearing capacity, negative pregnancy test prior to surgery and willingness to use birth control for the duration of the trial. 11. Medically able to undergo craniotomy as determined by the site PI and/or investigators 12. Medically able to tolerate the immunosuppression regimen as determined by the site PI Exclusion: 1. Using invasive ventilatory assistance 2. Diagnosis of another active or unstable medical illness that may interfere with study participation at discretion of PI 3. Presence of any of the following conditions: 1. Current drug or alcohol abuse 2. Any known immunodeficiency syndrome 3. Unstable medical condition 4. Unstable psychiatric illness including psychosis and untreated major depression within 90 days of screening 4. Persons of child bearing capacity not willing to practice birth control 5. Receiving any investigational device/biologic/drug in the past 30 days or any previous exposure to stem cell therapy 6. Any condition in the upper extremities that precludes serial strength or coordination testing 7. Any condition that the investigators feel may pose complications for the surgery 8. Any condition or ALS disease phenotype that the site PI feels may interfere with participation in the study or in the interpretation of study endpoints 9. Allergy to Beta-Lactam antibiotics 10. Donor Specific Antibodies (DSA) ≥ 2500MFI or CPRA ≥ 20% 11. Contraindications to MRI

Locations (1)

Cedars-Sinai Medical Center

Los Angeles, California, United States